The D2 antagonist sulpiride modulates the neural processing of both rewarding and aversive stimuli in healthy volunteers by Ciara McCabe et al.
ORIGINAL INVESTIGATION
The D2 antagonist sulpiride modulates the neural processing
of both rewarding and aversive stimuli in healthy volunteers
Ciara McCabe & Anna Huber & Catherine J. Harmer &
Philip J. Cowen
Received: 10 September 2010 /Accepted: 22 March 2011 /Published online: 15 April 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract
Rationale Animal studies indicate that dopamine pathways
in the ventral striatum code for the motivational salience of
both rewarding and aversive stimuli, but evidence for this
mechanism in humans is less established. We have
developed a functional magnetic resonance imaging (fMRI)
model which permits examination of the neural processing
of both rewarding and aversive stimuli.
Objectives The aim of the study was to determine the effect
of the dopamine receptor antagonist, sulpiride, on the
neural processing of rewarding and aversive stimuli in
healthy volunteers.
Methods We studied 30 healthy participants who were
randomly allocated to receive a single dose of sulpiride
(400 mg) or placebo, in a double-blind, parallel-group
design. We used fMRI to measure the neural response to
rewarding (taste or sight of chocolate) and aversive stimuli
(sight of mouldy strawberries or unpleasant strawberry taste)
4 h after drug treatment.
Results Relative to placebo, sulpiride reduced blood oxy-
genation level-dependent responses to chocolate stimuli in
the striatum (ventral striatum) and anterior cingulate cortex.
Sulpiride also reduced lateral orbitofrontal cortex and insula
activations to the taste and sight of the aversive condition.
Conclusions These results suggest that acute dopamine
receptor blockade modulates mesolimbic and mesocortical
neural activations in response to both rewarding and
aversive stimuli in healthy volunteers. This effect may be
relevant to the effects of dopamine receptor antagonists in
the treatment of psychosis and may also have implications
for the possible antidepressant properties of sulpiride.
Keywords Dopamine . Reward . D2 antagonist . Sulpiride .
fMRI . Ventral striatum
Introduction
Recent advances in neuroimaging have allowed the identifi-
cation of the neural systems activated during reward process-
ing and motivational behaviour in humans (Knutson and
Cooper 2005). Studies using functional magnetic resonance
imaging (fMRI) have revealed increased activity in the
ventral striatum during the presentation of primary or
secondary rewarding stimuli such as pleasant pictures,
music, food, or monetary reward (Blood and Zatorre 2001;
Lane et al. 1997; O’Doherty et al. 2001a, b). The medial
prefrontal cortex and the anterior/pregenual cingulate are
also reported to be important in the neural response to
pleasant stimuli and reward-motivated behaviour (Bechara et
al. 1996; Kahnt et al. 2010; Kringelbach et al. 2003; Rolls et
al. 2003b, 2010; Rolls and McCabe 2007). Conversely,
aversive stimuli have been found to activate the lateral
orbitofrontal cortices, the amygdala and caudate nuclei
(Fitzgerald et al. 2004; Rolls et al. 2003a; Zald et al. 2002).
Dopamine pathways are known to play a key role in
reward-based mechanisms through dopamine release from
ventral tegmental area neurons at their terminals in the nucleus
accumbens, ventral striatum (Bjorklund and Dunnett 2007).
Moreover, the role of dopamine extends to the processing of
aversive stimuli, giving rise to the notion that dopamine
pathways determine the motivational salience of environ-
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mental stimuli whether positively or negatively valenced
(Matsumoto and Hikosaka 2009). Previous studies which
have examined the influence of dopamine manipulation
on the neural processes of reward and punishment in
humans are consistent with this proposal. For example,
(Knutson et al. 2004) found that amphetamine adminis-
tration modulated prefrontal and striatal activations
produced by monetary reward and loss, whilst Menon
et al. (2007) reported that the dopamine receptor
antagonist, haloperidol, abolished the striatal response
to the prediction error involved in learning an aversive
conditioned response.
We have developed an experimental paradigm which
allows the study of the neural responses to primary and
secondary rewarding and aversive stimuli in the human
brain using fMRI. Using this approach, we have been able
to show that the chocolate stimuli activate parts of the
reward system such as the striatum, the medial orbitofrontal
cortex and pregenual cingulate gyrus, whereas the unpleas-
ant strawberry conditions activate the lateral orbitofrontal
cortex and insula cortex (McCabe et al. 2010; Rolls and
McCabe 2007). We have also shown that unmedicated
patients recovered from depression have reduced ventral
striatal responses to primary reward, suggesting trait
abnormalities in reward mechanisms in those at risk of
mood disorder (McCabe et al. 2009). The aim of the present
study was to use the dopamine receptor antagonist,
sulpiride, to examine the effects of dopamine D2/D3
receptor blockade on the neural responses to rewarding
and aversive stimuli in our model. We hypothesised that
sulpiride would lower the response in ventral striatum to
chocolate reward and also diminish the neural processing of
an aversive taste in lateral orbitofrontal cortex.
Materials and methods
Participants
Thirty healthy volunteers were randomised to receive a
single oral dose with sulpiride (400 mg, n=15), or placebo
(n=15), in a double-blind between-groups design. We used
a between-groups design to minimise the effects of practice
or habituation to the stimuli used in this study. Volunteers
were also matched for age and gender (see Table 1). Ethical
approval was provided by the Oxford Research Ethics
Committee B and written informed consent was obtained
from all participants before screening and after a complete
description of the study was given. Exclusion criteria for all
subjects were current or past Axis-1 disorder on the Structured
Clinical Interview for DSM-IV (Spitzer et al. 2004) and any
contraindications to MRI, e.g. pacemaker, mechanical heart
valve, hip replacement, metal implants.
None of the participants took current medication apart from
the contraceptive pill. Before drug administration and to ensure
group matching, baseline information was collected using the
Beck Depression Inventory (BDI; Beck et al. 1961), State-
Trait Anxiety Inventory (Spielberger 1983), the Fawcett–
Clarke Pleasure Scale (FCPS; Fawcett et al. 1983), and the
Snaith–Hamilton Pleasure Scale (SHAPS; Snaith et al. 1995).
The participants also completed a “chocolate questionnaire”
to measure liking, craving and frequency of eating chocolate
(Rolls and McCabe 2007). Body mass index (BMI) was also
calculated for each volunteer. To assess the effects of the
treatment, the following questionnaires were taken before and
after the treatment: visual analogue scales (VAS) of happi-
ness, sadness, anger, disgust, alertness and anxiety, and the
State Anxiety Inventory (Spielberger 1983). Volunteers also
completed the Positive Affect Negative Affect Schedule
(PANAS; Watson et al. 1988) before and after the treatment.
Overall design
We compared brain responses to rewarding and aversive
stimuli across the two drug groups. Each of the following
conditions were applied nine times in a randomised order
(see Electronic supplementary material (ESM) Table S1):
chocolate in the mouth, chocolate picture, chocolate in the
mouth with chocolate picture, strawberry in the mouth,
strawberry picture, strawberry in the mouth with strawberry
picture. Subjective effects of the stimuli were measured by
psychophysical ratings of “pleasantness”, “intensity” and
“wanting” made on every trial by the subjects during the
fMRI acquisition. The participants were instructed not to
eat chocolate for 24 h before the scan and to eat only a
small lunch on the day of scanning. Mood state was
recorded on the study day with the BDI (Beck et al. 1961).





Age (years) 22 (3.3) 22 (2.2)
Gender, M/F 7/8 8/7
BDI 1.8 (2.3) 2 (3.8)
TRAIT 34 (7.4) 36 (8.1)
FCPS 130 (14.4) 127 (16.5)
SHAPS 21 (3) 21 (4)
BMI 22 (2) 22.7 (3)
Choc craving 6.5 (1.6) 6.7 (1.7)
Choc liking 7.6 (1.7) 8.1 (1.3)
Choc freq eat 2.8 (2) 2.8 (1.8)
One-way ANOVAs, all p>0.077
BDI Beck Depression Inventory, FCPS Fawcett–Clarke Pleasure
Scale, SHAPS Snaith–Hamilton Pleasure Scale, BMI body mass index
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Stimuli
Stimuli were delivered to the subject’s mouth through three
Teflon tubes (one for the tasteless rinse control described
below, one for chocolate taste and one for strawberry taste);
the tubes were held between the lips. Each tube was
connected to a separate reservoir via a syringe and a one-
way syringe activated check valve (model 14044-5, World
Precision Instruments, Inc.), which allowed 0.5 ml of any
stimulus to be delivered manually at the time indicated by
the computer. The chocolate was formulated to be liquid at
room temperature, with a list of the six stimulus conditions
described in Table 1. A control tasteless solution, 0.5 mL of
a saliva-like rinse solution (25×10−3 mol/L KCl and 2.5×
10−3 mol/L NaHCO3 in distilled H20), was used between
trials (tl in ESM Table S1); when subtracted from the
effects of the other stimuli, this allowed somatosensory and
any mouth movement effects to be subtracted from the
effects produced by the other oral stimuli (de Araujo et al.
2003a; O’Doherty et al. 2001c). This allows the taste,
texture and olfactory areas to be shown independently of
any somatosensory effects produced by introducing a fluid
into the mouth (de Araujo et al. 2003a, b; de Araujo and
Rolls 2004; O’Doherty et al. 2001c). The aversive stimulus
was a strawberry drink (Rosemount Pharmaceuticals Ltd.)
which was rated as intense as the chocolate, but unpleasant
in valence (McCabe et al. 2009). Both the liquid chocolate
and the strawberry had approximately the same sweetness
and texture, which enabled them to pass freely through the
Teflon delivery tubes.
Experimental procedure
At the beginning of each trial, one of the six stimuli chosen
by random permutation was presented. If the trial involved
an oral stimulus, this was delivered in a 0.5-mL aliquot to
the subject’s mouth. At the same time, at the start of the
trial, a visual stimulus was presented, which was either the
picture of chocolate, of mouldy strawberries or a grey
control image of approximately the same intensity. The
image was turned off after 7 s, at which time a small green
cross appeared on a visual display to indicate to the subject
to swallow what was in the mouth. After a delay of 2 s, the
subject was asked to rate each of the stimuli for
“pleasantness” on that trial (with +2 being very pleasant
and −2 very unpleasant), for “intensity” on that trial (0 to +4)
and for “wanting” (+2 for wanting very much, 0 for neutral,
and −2 for very much not wanting). The ratings were made
with a VAS in which the subject moved the bar to the
appropriate point on the scale using a button box. After the
last rating, the grey visual stimulus indicated the delivery of
the tasteless control solution, which was also used as a rinse
between stimuli; this was administered in exactly the same
way as a test stimulus, and the subject was cued to swallow
after 7 s by the green cross. The tasteless control was always
accompanied by the grey visual stimulus. On trials on which
only the picture of chocolate was shown, there was no rinse,
but the grey visual stimulus was shown in order to allow an
appropriate contrast, as described below. There was then a 2-s
delay period that allowed for swallowing followed by a 1-s
gap until the start of the next trial. A trial was repeated for each
of the six stimulus conditions shown in ESM Table S1, and
the whole cycle was repeated nine times. The instruction
given to the subject was (on oral delivery trials) to move the
tongue once as soon as a stimulus or tasteless solution was
delivered in order to distribute the solution round the mouth to
activate the receptors for taste and smell, and then to keep still
for the remainder of the 7-s period until the green cross was
shown, when the subject could swallow. This procedure has
been shown to allow taste effects to be demonstrated clearly
with fMRI using the procedure of subtracting any activations
produced by the tasteless control from those produced by a
taste or other stimulus (de Araujo et al. 2003a, b; de Araujo
and Rolls 2004; O’Doherty et al. 2001c).
fMRI scan
The experimental protocol consisted of an event-related
interleaved design using in random permuted sequence the
six stimuli described above and shown in ESM Table S1.
Images were acquired with a 3.0-T Varian/Siemens whole-
body scanner at the Oxford Centre for Clinical Magnetic
Resonance Imaging where T2*-weighted EPI slices were
acquired every 2 s (TR=2). Imaging parameters were
selected to minimise susceptibility and distortion artefact
in the orbitofrontal cortex (Wilson et al. 2002). Coronal
slices (33) with in-plane resolution of 3×3 mm and
between plane spacing of 4 mm were obtained. The matrix
size was 64×64 and the field of view was 192×192 mm.
Acquisition was carried out during the task performance,
yielding 972 volumes in total. A whole brain T2*-weighted
EPI volume of the above dimensions and an anatomical T1
volume with coronal plane slice thickness 3 mm and in-
plane resolution of 1.0×1.0 mm were also acquired.
fMRI analysis
The imaging data were analysed using SPM8 (http://www.
fil.ion.ucl.ac.uk/spm/). Pre-processing of the data used
realignment, reslicing with sinc interpolation, normalisation
to the Montreal Neurological Institute (MNI) coordinate
system and spatial smoothing with a 6-mm full width at
half-maximum isotropic Gaussian kernel. Time series
non-sphericity at each voxel was estimated and corrected
for (Friston et al. 2002), and a high-pass filter with a
cutoff period of 128 s was applied. In the single event
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design, a general linear model was then applied to the time
course of activation where stimulus onsets were modelled
as single impulse response functions and then convolved
with the canonical haemodynamic response function
(Friston et al. 1994). Linear contrasts were defined to test
specific effects. Time derivatives were included in the
basis functions set. Following smoothness estimation,
linear contrasts of parameter estimates were defined to
test the specific effects of each condition with each individual
dataset. Voxel values for each contrast resulted in a statistical
parametric map of the corresponding t statistic, whichwas then
transformed into the unit normal distribution (SPM Z). The
statistical parametric maps from each individual dataset were
then entered into second-level, random effects analyses
accounting for both scan-to-scan and subject-to-subject vari-
ability. SPM converts the t statistics to Z scores (Table 2). We
examined simple main effects of group with one-sample t
tests, for all chocolate stimuli together or all strawberry
stimuli, thresholded at p=0.001 and whole brain cluster-
corrected (p<0.05 family-wise errors (FWE) for multiple
comparisons). To assess between-group differences for each
condition, two-sample t tests were used, thresholded at
p=0.05 and whole brain cluster-corrected (p<0.05 FWE for
multiple comparisons). We examined between-group differ-
ences for all the positive chocolate together, all the aversive
strawberry together and for each contrast separately. Plots of
contrast estimates are extracted using the plots tool in SPM8.
Coordinates of the activations are listed in the stereotactic
space of The Montreal Neurological Institute’s ICBM152
brain (Table 2 and ESM Table S3).
Results
Demographic details and mood ratings
There were no significant differences between the two
groups as determined by one-way ANOVAs for age,
gender, BMI, chocolate liking and attitudes to food
(EAT), all (p>0.07, Table 1). There were no significant
differences between the two groups as determined by one-
way ANOVAs for measures of anhedonia (SHAPS, FCPS)
or mood (BDI) (all p>0.07, Table 1). There were no
significant effects of group [F(1,27)=1.6, p=0.2], between
the sulpiride- and placebo-treated groups on VAS (alertness,
disgust, drowsiness, anxiety, happiness, nausea and sadness)
or PANAS [F(1,27)=0.36, p=0.55], as determined by
repeated measures ANOVAs (ESM Table S2).
Ratings of stimuli
Ratings of pleasantness, intensity and wanting for the
stimuli were obtained during the scanning on each trial
for every condition. All subjects rated the strawberry
picture and taste as unpleasant and the chocolate stimuli
as pleasant. Using repeated measures ANOVA with
“ratings” as a first factor with three levels—pleasantness,
intensity and wanting—and “condition” as a second factor
with six levels (see ESM Table S1 for six condition levels),
there was no significant effect of group [F(1,28)=1.6,
p=0.2] or group × condition interaction [F(1,28)=1.72,
p=0.2] (see ESM Fig. S1).
fMRI responses
ESM Table S3 provides a summary of the main effects of
one-sample t tests for the positive chocolate stimuli and the
aversive strawberry stimuli. Table 2 provides a summary of
the results of the interaction with group.
Main effect of task
As expected, the positive chocolate stimuli activated
reward-relevant circuitry including the ventral striatum,
the putamen, the anterior insula and parts of the anterior
cingulate cortex. The unpleasant strawberry stimuli activated
areas involved in aversive processing including the posterior
insula cortex and the lateral orbitofrontal cortex, but not the
ventral striatum (ESM Table S3).
Effect of sulpiride on chocolate reward
The sulpiride group, compared to placebo, showed less
blood oxygenation level-dependent (BOLD) activation to
the chocolate stimuli in the areas known to play a key role
in reward, including the ventral striatum and the anterior
cingulate cortex (Figs. 1a, b and 2a, b.).
Effect of sulpiride on aversive strawberry
The sulpiride group relative to placebo showed less BOLD
activation to the strawberry stimuli in areas known to play a
key role in processing aversive stimuli including the lateral
orbitofrontal cortex and insula, as illustrated in Fig. 3.
Relative to placebo, the sulpiride group also had less BOLD
activation to the unpleasant strawberry taste in the
precentral gyrus (Table 2).
Discussion
Our results indicate that a single dose of the D2/3 receptor
antagonist, sulpiride, can decrease the neural processing of
reward in the ventral striatum and anterior cingulate despite
no change in subjective mood. Furthermore, we found that
sulpiride decreased activation to the aversive sight and taste
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of mouldy strawberries in the insula and lateral orbito-
frontal cortex.
The decreased striatal activation to reward seen with
sulpiride is in keeping with our hypothesis that inhibition of
dopamine transmission would negatively impact on the
neural processing of pleasant stimuli. A recent study which
examined the effects of a single dose of the antipsychotic
olanzapine on neural processing of delayed incentive salience
of monetary reward in healthy volunteers also reported
reduced ventral striatal activation (Abler et al. 2007), whilst
Knutson et al. (2004) found that the dopamine agonist
amphetamine increased the duration (but decreased the peak)
of ventral striatal response to win anticipation. Interestingly,
a hyperactive striatal response to reward was also found in
patients with schizophrenia, supporting the notion that
psychosis may represent a state of abnormal salience
(Kapur 2003). From this viewpoint, dopamine receptor
antagonists may produce therapeutic benefit in psychosis
by decreasing the tendency of patients to ascribe novelty
and motivational importance to irrelevant stimuli. Unfor-
tunately, this effect of antipsychotic drugs may also be
directed towards normal motivational drives, perhaps
accounting for the association of antipsychotic treatment
with emotional blunting and indifference to normal social
reinforcers.
We also found decreased activation to the aversive
stimuli in brain regions such as the lateral orbitofrontal
cortex and the insula which have been previously shown
to encode the processing of unpleasant stimuli (Fitzgerald
et al. 2004; Small et al. 2001) and specifically also in the
current model of aversion processing (Horder et al. 2010;
McCabe et al. 2009, 2010). Interestingly, therefore, it




Ventral Striatum 14 16 −2 3.40 (2445) 0.05a
Chocolate in the mouth plus the sight of chocolate
Placebo > Sulpiride
Anterior cingulate 10 16 30 3.33 (2205) 0.05
0 4 34 3.04 (2205) 0.05
Temporal gyrus 34 −26 8 3.44 (5860) <0.001
All straw stimuli
Placebo > Sulpiride
LOFC 34 32 −8 4.16 (2265) <0.001
Strawberry in the mouth:
Placebo > Sulpiride
Precentral gyrus 54 6 38 3.65 (745) <0.001a
Insula 34 16 10 3.33 (745) <0.001a
Table 2 Regions showing
significant effect of treatment
on each condition relative
to placebo




a Thresholded at p=0.01 uncor-
rected; whole brain fully corrected
cluster level (p<0.05 FWE for
multiple comparisons)
Fig. 1 a All chocolate stimuli
(placebo vs. sulpiride): Axial,
sagittal and coronal image of
decreased ventral striatum in the
sulpiride group compared to the
placebo group, activations
thresholded at p=0.01
uncorrected and whole brain
cluster-corrected (p<0.05 FWE
for multiple comparisons). b
Contrast estimates for ventral
striatum at 14 16 −2 for
sulpiride and placebo
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seems that antipsychotics not only have the ability to
reduce the attribution of salience to rewarding stimuli but
also are able to dampen the response to negatively
valenced stimuli. These results therefore support the idea that
dopamine is involved in the salience of both positive and
negative events (Knutson et al. 2004; Schultz 2010a, b).
Furthermore, recent studies examining the effects of phar-
macological manipulation of dopamine in both Parkinson’s
disease (PD) and Tourette’s syndrome found that dopamine
enhancement in PD enhanced reward learning and dopamine
blockade in Tourettes enhanced punishment avoidance
(Palminteri et al. 2009). These data suggest that modulating
dysfunctional dopamine systems enhances decision making
by redressing the reward–punishment imbalance. Preclinical
studies on the effects of antipsychotics also indicate that
dopamine blockade in the striatum disrupts avoidance
performance and that this may be due to the reduced
activation of instrumental behaviour (Maia and Frank 2011).
Moreover, studies examining behavioural strategies in
response to uncertainty in schizophrenic patients implicate
decreased dopamine in the prefrontal complex as underpin-
ning such dysfunction (Strauss et al. 2011).
Reducing reactivity to and salience attribution of aversive
stimuli is a common goal in treatments of disorders charac-
terised by negative affectivity and may help explain why
antipsychotic drugs are sometimes found to be beneficial in the
treatment of anxiety and depression. In particular, substituted
benzamides such as sulpiride and amisulpiride are commonly
used clinically in some countries for the treatment of chronic
mood disorders such as dysthymia (Lecrubier et al. 1997).
Furthermore, a similar effect on aversive processing was also
seen with 7-day administration of the SSRI citalopram in our
model in healthy volunteers (McCabe et al. 2010).
Previous studies have shown that schizophrenia involves
hyperactivity of dopamine neurons in the basal ganglia, but
decreased activity in the prefrontal cortex (Epstein et al.
1999; Lewis 1995; Meyer-Lindenberg et al. 2002). It is
therefore of great interest that we found decreased
activation to the pleasant chocolate reward in the ventral
striatum yet did not find any increased prefrontal cortex
activity at the statistical threshold used here. It is important
to assess whether such effects may be seen with a larger
sample of volunteers and increased statistical power. The
current study used a between-subjects, placebo-controlled
Fig. 2 a Chocolate in the mouth
plus the sight of chocolate
(sulpiride vs. placebo): Axial,
sagittal and coronal image of
decreased anterior cingulate
cortex activation in the sulpiride
group compared to the placebo
group, activations thresholded at
p=0.05 uncorrected and whole
brain cluster-corrected (p<0.05
FWE for multiple comparisons).
b Contrast estimates for
anterior cingulate at 10 16 30
for sulpiride and placebo
Fig. 3 a All strawberry stimuli
(placebo vs. sulpiride): Axial,
sagittal and coronal image of
decreased LOFC activation in
the sulpiride group compared to
the placebo group, activations
thresholded at p=0.05 uncor-
rected and whole brain cluster-
corrected (p<0.05 FWE for
multiple comparisons). b
Contrast estimates for LOFC
at 34 32 −8 for sulpiride
and placebo
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design to minimise the effects of practice or habituation
to the stimuli used here. In future studies, we plan to
explore the effects of drug manipulations in this model
using a within-subjects design to minimise inter-subject
variability. Such an approach may ultimately improve
statistical power and be useful in the future application
of this model.
Taken together, the results from this study show that a
single dose of the antipsychotic drug sulpiride can
differentially modulate neural activity in response to
rewarding and aversive stimuli in healthy volunteers. These
findings may have implications for the mode of action of
drugs such as sulpiride in the treatment of psychosis and
mood disorders. Studies in patients will be required to see
whether the effects we have seen are related to the
therapeutic actions of sulpiride in clinical populations.
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